drugset / Trial / NCT02677038
Olaparib in Treating Patients With Stage IV Pancreatic Cancer
Phase 2
Completed
24 enrolled
M.D. Anderson Cancer Center
AstraZeneca · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well olaparib works in treating patients with stage IV pancreatic cancer. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2016-11-11
- Primary completion
- 2022-07-18
- Completion
- 2022-07-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | — | Oral |